NASDAQ:CSBR - Champions Oncology Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.10 +0.01 (+0.16 %)
(As of 07/15/2018 03:45 PM ET)
Previous Close$6.10
Today's Range$5.99 - $6.31
52-Week Range$2.19 - $7.60
Volume60,437 shs
Average Volume58,960 shs
Market Capitalization$67.11 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.29
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that use vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. The company markets its products through Internet, word of mouth, and a network of sales force to patients and physicians. Champions Oncology, Inc. has collaboration agreements with The Addario Lung Cancer Medical Institute and AstraZeneca to develop cohorts of PDX models. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Receive CSBR News and Ratings via Email

Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CSBR
CUSIPN/A
Phone201-808-8400

Debt

Debt-to-Equity RatioN/A
Current Ratio0.68
Quick Ratio0.68

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.41 million
Price / Sales4.35
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book152.50

Profitability

EPS (Most Recent Fiscal Year)($0.64)
Net Income$-6,880,000.00
Net Margins-17.17%
Return on Equity-854.38%
Return on Assets-46.60%

Miscellaneous

Employees79
Outstanding Shares11,000,000
Market Cap$67.11

The Truth About Cryptocurrencies

Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions

What is Champions Oncology's stock symbol?

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

How were Champions Oncology's earnings last quarter?

Champions Oncology Inc (NASDAQ:CSBR) issued its quarterly earnings results on Thursday, March, 15th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The biotechnology company earned $5.08 million during the quarter. Champions Oncology had a negative net margin of 17.17% and a negative return on equity of 854.38%. View Champions Oncology's Earnings History.

When is Champions Oncology's next earnings date?

Champions Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Champions Oncology.

What price target have analysts set for CSBR?

2 analysts have issued 1 year price objectives for Champions Oncology's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Champions Oncology's stock price to reach $10.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Ratings for Champions Oncology.

What is the consensus analysts' recommendation for Champions Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Champions Oncology's key competitors?

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the folowing people:
  • Dr. Ronnie Morris M.D., CEO & Director (Age 52)
  • Mr. David Barry Miller, Chief Financial Officer (Age 49)
  • Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 65)
  • Mr. Mark Weinstein, Chief Information Officer
  • Dr. Angela M. Davies M.D., FRCPC, Chief Medical Officer (Age 48)

Has Champions Oncology been receiving favorable news coverage?

Headlines about CSBR stock have been trending somewhat positive on Sunday, according to Accern Sentiment. Accern identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Champions Oncology earned a media sentiment score of 0.13 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.76 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Champions Oncology?

Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Champions Oncology's stock price today?

One share of CSBR stock can currently be purchased for approximately $6.10.

How big of a company is Champions Oncology?

Champions Oncology has a market capitalization of $67.11 million and generates $15.41 million in revenue each year. The biotechnology company earns $-6,880,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. Champions Oncology employs 79 workers across the globe.

How can I contact Champions Oncology?

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]


MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  124
MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.